Èñ¸Á¼Ò½Ä

Ȩ > Èñ¸Á¼Ò½Ä > ÀÚÀ¯°Ô½ÃÆÇ

ÀÚÀ¯°Ô½ÃÆÇ

IMETELSTAT - MDS ¹× MF Ä¡·á

Kmall ¦¢ 2019-07-12

IMETELSTAT - MDS ¹× MF Ä¡·á

 

¾È³çÇϼ¼¿äÀü IMETELSTAT¿¡ °üÇØ ¸ðµç È¯ÀÚ°¡Á· ¹× ÀÇ·á Á¾»çÀڵ鿡°Ô ¾Ë¸®°í ÀÚÇϴ ¹Ì±¹ÀÇ Àü °£º´ÀÎÀÔ´Ï´Ù. IMETELSTAT´Â GERONÀÌ °³¹ßÁßÀΠMDS ¹× MF Ä¡·á¿¡¼­ Åڷι̾ Å¸±êÀ¸·ÎÇϴ Èï¹Ì·Î¿î ½Å¾àÀÔ´Ï´Ù. P2 ÀÓ»ó ½ÃÇèÀº ³î¶ó¿î °á°ú·Î ¿Ï·áµÇ¾ú½À´Ï´ÙÄ¡·á¸¦À§ÇÑ ¼±ÅÃÀÇ ¿©Áö°¡ °ÅÀǾø´Â °÷¿¡¼­´Â ±Ø¼Ò¼öÀǠȯÀڵ鿡°Ô¼­ µ¹Æı¸°¡ µÉ °ÍÀ¸·Î º¸À̸翪Çà ÇÒ ¼öÀִ ºÎÀÛ¿ëÀ» ÁöÀûÇؾßÇÕ´Ï´Ù. 3 »ó ÀÓ»ó ½ÃÇèÀº 2019 ³â Á߹ݿ¡ ½ÃÀ۵ɠ¿¹Á¤À̸çÀ̴ °ð ±Û·Î¹ú ¸ðÁýÀÌ ½ÃÀ۵ɠ°ÍÀ̶ó´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. IMerge´Â Àú À§Ç蠶Ǵ Áß±Þ -1 À§ÇèÀ» Áö´Ñ ¼öÇ÷ ÀÇÁ¸ È¯ÀÚ¿¡¼­ IMETELSTAT¿¡ ´ëÇÑ 2 È¸ ÀÓ»ó ½ÃÇèÀ¸·Î, ESA·Î ÀÌÀü Ä¡·á·Î Àç¹ßÇ߰ųª ³­Ä¡ ¾ÊÀº Àú À§Çè MDS¶ó°íµµÇÕ´Ï´Ù. 2017 ³â 10 ¿ù¿¡´Â FDAÀÇ ½Å¼Ó Ã³¸® ÇöȲ¿¡ ´ëÇÑ ³ì»ö Ç¥½ÃµîÀÌ ÁÖ¾îÁ³½À´Ï´Ù¾Æ·¡ ¸µÅ©¿¡¼­ Á¦°ø ÇÑ 2018 ³â 12 ¿ù ASH ½ÉÆ÷Áö¾öÀÇ µ¥ÀÌÅÍ °ËÅ並 Àо½Ê½Ã¿À.

https://seekingalpha.com/article/4227473-geron-corporation-gern-investor-presentation-slideshow?dr=1

 

°ËÅä ÈÄ GERON¿¡ ¿¬¶ôÇÏ¿© ¸ðÁýÀÌ ¾ðÁ¦ ½ÃÀÛµÇ°í ¸ðÁý »çÀÌÆ®¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ´ÂÁö ¾Ë¾Æº¸½Ê½Ã¿À - https://www.geron.com/about/contact/

 

´Ü°è ÀÓ»ó ½ÃÇè À§Ä¡ »çÀÌÆ®´Â ´ÙÀ½ »çÀÌÆ®¿¡¼­ Ã£À» ¼ö ÀÖ½À´Ï´Ù - https://clinicaltrials.gov/ct2/show/study/NCT02598661?show_locs=Y#locn

(ÀÌ ±ÛÀ» ¾²°íÀִ ½ÃÁ¡¿¡¼­ P3ÀÇ »çÀÌÆ® À§Ä¡°¡ °°ÀºÁö È®½ÇÇÏÁö ¾Ê½À´Ï´Ù)

 

IMETELSTATÀº ¾ðÁ¨°¡ ¾Æ·¡ÀÇ ÃÊ·Ï¿¡ ¼³¸í µÈ´ë·Î ¸ðµç ¾Ï Áß 90 %¸¦ Å¸°ÙÀ¸·ÎÇÕ´Ï´Ù :

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4633-x 

 

IMETELSTATÀÌ ´ç½ÅÀ»À§ÇÑ ¼±Åà»çÇ×ÀÌ ¾Æ´Ï´õ¶óµµ³ª´Â ´ç½ÅÀÌ Á÷¸éÇÏ°íÀִ »óȲ¿¡ ´ëÇØ °¡´ÉÇÑ ¸ðµç ¿¬±¸¸¦ ÇÒ °ÍÀ» ´çºÎÇÕ´Ï´Ù¸¹Àº ¾ÏƯÈ÷ °ø°ÝÀûÀΠÇ÷¾×À» ¸Å°³·ÎÇϴ ¾ÏÀ» Ä¡·áÇÒ ¶§´Â ½Ã°£ÀÌ °¡Àå Áß¿äÇÕ´Ï´Ù¿©·¯ºÐ ¸ðµÎÀÇ Ä¡·á¿¡ ÃÖ¼±À» ±â¿øÇϸçÁ¦°¡ Á¦°ø ÇÑ Á¤º¸°¡ ¾î¶² ½Ä À¸·Îµç µµ¿òÀÌ µÉ ¼ö Àֱ⸦ ¹Ù¶ø´Ï´Ù¸ðµÎ Á¦ÀÏ ÁÁ´ÙÅ°À̽º

 

IMETELSTAT – Treatment for MDS and MF

 

Hello, I am a former caregiver from the United States who is interested in informing all patients, their family members and any medical practitioners here about IMETELSTAT.  It is an exciting new drug targeting telomeres in treating MDS and MF that is being developed by GERON.  It finished P2 trials with REMARKABLE results.  Where there are very few options for treatment this looks to be a break through with very few, and it should be noted REVERSIBLE side effects.  Phase 3 trials are set to begin in mid-2019, which means global recruitment will begin very soon.  IMerge is a two-part clinical trial of IMETELSTAT in transfusion dependent patients with Low or Intermediate-1 risk, also referred to as lower risk, MDS, who have relapsed after or are refractory to prior treatment with an ESA.  In October 2017 this was given the green light for FDA fast track status.  Please read the data review from this year¡¯s ASH symposium on Dec 2018  I have provided in the link below:

https://seekingalpha.com/article/4227473-geron-corporation-gern-investor-presentation-slideshow?dr=1

 

After reviewing please contact GERON to find out when recruitment will begin and where recruitment sites will be available – https://www.geron.com/about/contact/

 

Phase 2 location sites can be found at – https://clinicaltrials.gov/ct2/show/study/NCT02598661?show_locs=Y#locn

(as of this writing I am not sure if site locations for P3 will be the same)

 

IMETELSTAT has the potential of someday targeting 90% of all cancers as described in the abstract below:

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4633-x

 

Even if IMETELSTAT is not an option for you, I implore you to do all the research you possibly can for what ever condition you may be facing.  Time is of the essence and most crucial when dealing with many cancers, especially aggressive blood borne ones.  I wish all of you the best in your treatment and hope the information I have provided can help in any way possible.  All the best.  Kmall



ÀÛ¼ºÀÚ ºñ¹Ð¹øÈ£     ºñ¹Ð·ÎÇϱâ

³»¿ë

ÀÌÀü±Û °ñ¼öÇü¼ºÀÌ»óÁõÈıº Ã¥ÀÚ¸¦ ¹Þ¾Æº¸°í ½Í½À´Ï´Ù.
´ÙÀ½±Û Èñ¸ÁÁö ¹Þ¾Æº¸°í ½Í½À´Ï´Ù